Abstract: Provided is a novel bleomycin hydrolase production promotor Provided is a bleomycin hydrolase production promotor, natural moisturizing factor production promotor, and dry skin remedy, comprising as an active ingredient thereof one or a plurality of ingredients selected from the group consisting of chestnut rose extract, angelica root extract, cork tree bark extract, lamium album extract, rosemary extract, benzenesulfonyl GABA and erythritol.

Abstract: The present invention provides an antibody specific to a C-terminal domain of a human profilaggrin gene, wherein the C-terminal domain is a peptide comprising the amino acid sequence set forth in SEQ ID NO:1 or a variant thereof, a method for detecting a filaggrin gene mutation using the antibody, and a kit for the detection.

Abstract: The present invention provides a method for screening and evaluating ameliorants of dry skin caused by atopic dermatitis, comprising: evaluating a candidate drug as being an ameliorant of dry skin caused by atopic dermatitis in the case the candidate drug significantly increases expression and/or activity of bleomycin hydrolase in comparison with a control drug.

Abstract: The invention provides a method for evaluating skin condition using squamous cell carcinoma antigen (SCCA) expression in skin stratum corneum cells as a marker.

Abstract: The present invention provides a method for screening and evaluating ameliorants of dry skin caused by atopic dermatitis, comprising: evaluating a candidate drug as being an ameliorant of dry skin caused by atopic dermatitis in the case the candidate drug significantly increases expression and/or activity of bleomycin hydrolase in comparison with a control drug.

Abstract: The present invention provides a method for screening and evaluating ameliorants of dry skin caused by atopic dermatitis, comprising: evaluating a candidate drug as being an ameliorant of dry skin caused by atopic dermatitis in the case the candidate drug significantly increases expression and/or activity of bleomycin hydrolase in comparison with a control drug.

Abstract: The present invention provides an antibody specific to a C-terminal domain of a human profilaggrin gene, wherein the C-terminal domain is a peptide comprising the amino acid sequence set forth in SEQ ID NO:1 or a variant thereof, a method for detecting a filaggrin gene mutation using the antibody, and a kit for the detection.

Abstract: Provided is a novel bleomycin hydrolase production promoter. Provided is a bleomycin hydrolase production promoter, natural moisturizing factor production promoter, and dry skin remedy, comprising as an active ingredient thereof one or a plurality of ingredients selected from the group consisting of chestnut rose extract, angelica root extract, cork tree bark extract, lamium album extract, rosemary extract, benzenesulfonyl GABA and erythritol.

Abstract: The invention provides a screening method for chronic inflammation inhibitors or cancer metastasis inhibitors wherein, when a candidate substance as a chronic inflammation inhibitor or cancer metastasis inhibitor significantly inhibits binding between EMMPRIN and S100A9 or S100A8/A9, the candidate substance is evaluated as significantly suppressing chronic inflammation or cancer metastasis.

Abstract: The present invention provides a method for screening and evaluating ameliorants of dry skin caused by atopic dermatitis, comprising: evaluating a candidate drug as being an ameliorant of dry skin caused by atopic dermatitis in the case the candidate drug significantly increases expression and/or activity of bleomycin hydrolase in comparison with a control drug.

Abstract: The present invention provides a screening method for a substance capable of promoting recovery of skin barrier function, wherein the method comprises the steps of incubating caspase-14 and prosaposin in the presence of a candidate substance for the substance capable of promoting recovery of skin barrier function, and selecting the candidate substance as the substance capable of promoting recovery of skin barrier function when the degradation of prosaposin into saposin A is promoted significantly compared to a control substance.

Abstract: In a first aspect thereof, the present invention provides a method for treatment and/or prevention of a disease selected from the group consisting of psoriasis and squamous cell carcinoma by inhibiting the expression of squamous cell carcinoma antigen (SCCA) by cells. In another aspect thereof, the present invention provides a method for screening for substances that inhibit epidermal parakeratosis, wherein the activity of a candidate substance that inhibits cysteine protease inhibitory activity possessed by squamous cell carcinoma antigen 1 (SCCA-1) is used as an indicator.

Abstract: The present invention provides a method for evaluating the status of the skin barrier function of natural moisturizing factor (NMF) using the activity of bleomycin hydrolase in skin tissue as an indicator.

Abstract: In a first aspect thereof, the present invention provides a method for treatment and/or prevention of a disease selected from the group consisting of psoriasis and squamous cell carcinoma by inhibiting the expression of squamous cell carcinoma antigen (SCCA) by cells. In another aspect thereof, the present invention provides a method for screening for substances that inhibit epidermal parakeratosis, wherein the activity of a candidate substance that inhibits cysteine protease inhibitory activity possessed by squamous cell carcinoma antigen 1 (SCCA-1) is used as an indicator.

Abstract: The present invention provides a method for evaluating the degree of skin sensitivity by using the expression of squamous cell carcinoma antigen (SCCA) in skin corneocytes as an indicator thereof.

Abstract: In a first aspect thereof, the present invention provides a method for treatment and/or prevention of a disease selected from the group consisting of psoriasis and squamous cell carcinoma by inhibiting the expression of squamous cell carcinoma antigen (SCCA) by cells. In another aspect thereof, the present invention provides a method for screening for substances that inhibit epidermal parakeratosis, wherein the activity of a candidate substance that inhibits cysteine protease inhibitory activity possessed by squamous cell carcinoma antigen 1 (SCCA-1) is used as an indicator.

Abstract: There is provided a hair tonic comprising at least two of an inhibitor against 5? reductase type 2, an inhibitor against transforming growth factor ?2, and an inhibitor against caspase-3; a method comprising screening for at least two of inhibition against 5? reductase type 2, inhibition against transforming growth factor ?2, and inhibition against caspase-3, or comprising screening for inhibition against caspase-3 and then for apoptosis inhibition, and a hair loss inhibitor having the effect of inhibiting caspase-3, and a hair loss inhibitor having the effect of inhibiting caspase-3 and of inhibiting apoptosis.

Abstract: The present invention provides a method for enhancing resistance to the onset of skin damage caused by irradiation of the skin with ultraviolet light by inhibiting ultraviolet irradiation-induced apoptosis of epidermal cells as a result of increasing expression of SCCA-1 and/or SCCA-2 in epidermal cells. Moreover, the present invention provides a skin testing method for evaluating resistance of the skin to skin damage caused by ultraviolet irradiation by measuring the expression of SCCA-1 and/or SCCA-2 in epidermal cells, and judging UV resistance of the epidermis to be weak in the case expression is decreased as compared with expression in epidermal cells. Moreover, the present invention provides a method for screening drugs which enhance resistance of the skin to skin damage by ultraviolet irradiation by selecting a drug that increases expression of SCCA-1 and/or SCCA-2 as a UV resistance enhancer.

Abstract: There is provided a hair tonic comprising at least two of an inhibitor against 5? reductase type 2, an inhibitor against transforming growth factor ?2, and an inhibitor against caspase-3; a method comprising screening for at least two of inhibition against 5? reductase type 2, inhibition against transforming growth factor ?2, and inhibition against caspase-3, or comprising screening for inhibition against caspase-3 and then for apoptosis inhibition, and a hair loss inhibitor having the effect of inhibiting caspase-3, and a hair loss inhibitor having the effect of inhibiting caspase-3 and of inhibiting apoptosis.

Abstract: The present invention provides a method and composition that inhibit the kinase activity of JNK-1 (c-Jun N-terminal kinase 1) in cells by increasing the expression of squamous cell carcinoma antigen (SCCA) in cells.